Soares, Carolina http://orcid.org/0000-0002-2338-4495
Da Ros, Lucas Uglione
Machado, Luiza Santos http://orcid.org/0000-0001-8387-3832
Rocha, Andreia http://orcid.org/0000-0003-1567-3374
Lazzarotto, Gabriela
Carello-Collar, Giovanna
De Bastiani, Marco A. http://orcid.org/0000-0003-3924-5278
Ferrari-Souza, João Pedro
Lussier, Firoza Z.
Souza, Diogo O.
Rosa-Neto, Pedro
Pascoal, Tharick A. http://orcid.org/0000-0001-9057-8014
Bellaver, Bruna
Zimmer, Eduardo R. http://orcid.org/0000-0002-5349-0053
Article History
Received: 17 August 2023
Revised: 23 January 2024
Accepted: 31 January 2024
First Online: 16 February 2024
Competing interests
: E.R.Z. served in the SAB of Novo Nordisk, serves on SAB of Next Innovative Therapeutics (Nintx) and serves on the SAB and is a Co-founder of MASIMA. P.R-N. served in the SAB of Novo Nordisk, Eisai and Ely Lilly and as a Consultant in Eisai and Cerveau radiopharmaceuticals. Other authors declare no conflict of interest.